Bone marrow transplantation in patients with acute leukemia.
At least three factors may be responsible for leukemic relapse in patients receiving ABMT: (a) minimal residual disease; (b) leukemic cells reinfused with the graft; and (c) the lack of a graft-versus leukemia effect. Techniques for pharmacological marrow decontamination, clinical result obtained with ABMT and the efficacy of ABMT with mafosfamide purged marrow in patients with acute myelogenous leukemia are reviewed.